Global Secondary Myelofibrosis Market - 2023-2030

Global Secondary Myelofibrosis Market - 2023-2030

Global Secondary Myelofibrosis Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.

The global secondary myelofibrosis market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The increase in the number of polycythemia vera cases and the increase in the essential thrombosis condition are the driving factors of the market growth.

The treatments associated with secondary myelofibrosis include drugs, chemotherapy, and radiotherapy. Drugs act as the first line of treatment for their efficiency against the disease. Drugs segment accounts for over half of the market share. Similarly, the North American region is expected to hold a significant share with the increased clinical trials, approvals, and launches of the products. The presence of the major players in the region is driving the growth of the region in the market share.

Dynamics

Increase in the Prevalence of Polycythemia Vera will Drive the Market Growth

About 10% to 15% of the time, polycythemia vera changes into myelofibrosis. This is called post-polycythemia vera myelofibrosis. Myelofibrosis is a blood cancer in which bone marrow has so much scar tissue that it can't make enough healthy blood cells. An increase in the prevalence of polycythemia is driving the growth of the market. For instance, according to NIH, the prevalence of polycythemia vera has been estimated to be approximately 22 cases per 100,000 population.

Polycythemia vera affects slightly more men than women. Additionally, according to the National Organization for Rare Disorders (NORD), the disorder is estimated to affect approximately 44 to 57 per 100,000 people in the US. It occurs most often in individuals over 60 years old but can affect individuals of any age. It is extremely rare in individuals under 20. Thus, the increase in polycythemia vera is expected to drive market growth.

Rise in the Essential Thrombosis will Elevate the Market Growth

Essential thrombosis is a hematology malignancy that increases the risk of developing secondary myelofibrosis. An increase in essential thrombosis cases is driving the market growth. For instance, according to the Leukemia and Lymphoma Society, the incidence (newly diagnosed cases) of ET for all races and ethnicities is approximately 2.2 per 100,000 population each year. ET occasionally occurs in older children but is mostly diagnosed in adult men and women.

Thrombocytopenia in MF has multiple causes, including ineffective hematopoiesis, splenic sequestration, and treatment-related effects. Due to thrombocytosis, there are risks of vascular events such as thrombosis and hemorrhage and sometimes the conversion to a blast phase of myelofibrosis. Thus, an increase in essential thrombosis will raise the market growth in the forecast period.

Lack of Awareness of the Disease Condition and its Treatment can Impede Market Growth

Lack of awareness of the disease condition and its treatment can impede market growth. Myelofibrosis causes extensive scarring in the bone marrow and a lack of awareness of the symptoms, and the disease can lead to severe anemia that can cause weakness and fatigue. Bone marrow scarring can also cause a low number of blood-clotting cells called platelets, which increases the risk of bleeding.

Long-standing secondary myelofibrosis in response to bone marrow hematopoietic tissue or vascular injury may lead to similar peripheral blood alterations, including moderate to severe nonregenerative anemia with extensive extramedullary hematopoiesis, leukopenia, and alterations in platelet numbers. Red blood cell morphologic abnormalities are also reported. Thus, the above factors will decline the market growth.

Segment Analysis

The global secondary myelofibrosis market is segmented based on treatment, end user and region.

Drugs Segment Holds a Dominant Share in the Secondary Myelofibrosis Market

Secondary myelofibrosis is a group of diseases in which bone marrow hematopoietic tissue fibrosis caused by various causes affects hematopoietic function. Treatment options for secondary MF vary depending on the severity of the cancer case and the symptoms the patient is experiencing. The drug segment is expected to hold a dominant market share due to the efficiency of the drugs against the disease. Drugs target the JAK1 and/or JAK2 proteins that help regulate blood. They can treat and lessen some of the symptoms of myelofibrosis, including an enlarged spleen, night sweats, itching, and bone or muscle pain.

They can work in both patients that have a JAK2 mutation and those that do not. Jakafi, Inrebic, and Vonjo are U.S. Food and Drug Administration (FDA)-approved drugs for treating intermediate or high-risk myelofibrosis. All three drugs are JAK inhibitors that reduce overactive Janus-associated kinase (JAK) signaling. Thus, the above factors hold the segment in the dominant position in the market share.

Geographical Penetration

North America Holds a Significant Position in the Market Share

North America has been a dominant force in the global secondary myelofibrosis market. The increase in the number of clinical trials and approvals of the products is driving the market growth in this region. For instance, on April 12, 2022, AbbVie announced new data from a Phase 2 trial of navitoclax in combination with ruxolitinib in patients with myelofibrosis.

The results were presented at the annual American Association for Cancer Research meeting (AACR 2022). Navitoclax is an investigational, first-in-class, oral BCL-XL/BCL-2 inhibitor designed to activate programmed cell death (apoptosis) in cancer cells. Navitoclax and its safety and efficacy are under evaluation as part of ongoing Phase 2 and registrational Phase 3 studies.

Additionally, on March 09, 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and NATCO Pharma Limited announced the launch of additional strengths for the generic version of Revlimid (lenalidomide capsules) in 2.5 mg and 20 mg strengths, in the United States. Thus, the increased clinical trials and launches of the products are expected to hold a dominant market share.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical markets worldwide, including the global secondary myelofibrosis market. As countries grappled with lockdowns, supply chain disruptions and treatment of the disease were interrupted.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting the revenues of pharmaceutical companies. The manufacturing processes of the drugs and related products were interrupted due to insufficient raw materials. The companies halted the production of the drugs as they shifted their focus toward the treatment procedures for COVID-19.

By Treatment
• Based on Therapy
Chemotherapy
Radiation Therapy
• Based on Bone Marrow Transplantation
Allogeneic Stem Cell Transplantation
Autologous Stem Cell Transplantation
• Based on Drugs
Jakafi
Inrebic
Vonjo

By End User
• Hospitals
• Specialty Clinics
• Academic and Research Institutes
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Russia
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In February, 2022, CTI BioPharma Corp. announced that the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the first approved therapy that specifically addresses the needs of patients with cytopenic myelofibrosis.
• On December 20, 2022, Imago BioSciences, Inc., a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi) in people with myelofibrosis (MF). Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including intermediate or high-risk MF treatment.

Competitive Landscape

The major global players in the market include Novartis Pharma AG, MANUS AKTTEVA BIOPHARMA LLP, Bristol-Myers Squibb, GNH India Pharmaceuticals Limited, CTI BIOPHARMA CORP., Dr. Reddy's Laboratories, Incyte Corporation, Pfizer Inc., GlaxoSmithKline Pharmaceuticals Ltd, Anant Pharmaceuticals Pvt Ltd among others.

Why Purchase the Report?
• To visualize the global secondary myelofibrosis market segmentation based on treatment, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of secondary myelofibrosis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global secondary myelofibrosis market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies